177 related articles for article (PubMed ID: 33251859)
1. Vaccine development against methamphetamine drug addiction.
Hossain MK; Hassanzadeganroudsari M; Nurgali K; Apostolopoulos V
Expert Rev Vaccines; 2020 Dec; 19(12):1105-1114. PubMed ID: 33251859
[TBL] [Abstract][Full Text] [Related]
2. Immune to addiction: how immunotherapies can be used to combat methamphetamine addiction.
Hossain MK; Hassanzadeganroudsari M; Kypreos E; Feehan J; Apostolopoulos V
Expert Rev Vaccines; 2021 Jun; 20(6):707-715. PubMed ID: 33970739
[No Abstract] [Full Text] [Related]
3. Development of active and passive human vaccines to treat methamphetamine addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Hum Vaccin; 2009 Apr; 5(4):206-13. PubMed ID: 19276653
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for treating methamphetamine, heroin and cocaine use disorders.
Xiaoshan T; Junjie Y; Wenqing W; Yunong Z; Jiaping L; Shanshan L; Kutty Selva N; Kui C
Drug Discov Today; 2020 Mar; 25(3):610-619. PubMed ID: 31419495
[TBL] [Abstract][Full Text] [Related]
5. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
[TBL] [Abstract][Full Text] [Related]
6. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
7. Anti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Clin Pharmacol Ther; 2010 Sep; 88(3):390-3. PubMed ID: 20668443
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a novel conjugated methamphetamine vaccine.
Kamal Hossain M; Davidson M; Feehan J; Deraos G; Nurgali K; Matsoukas J; Apostolopoulos V
Vaccine; 2022 Sep; 40(41):5882-5891. PubMed ID: 36041942
[TBL] [Abstract][Full Text] [Related]
9. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.
Miller ML; Moreno AY; Aarde SM; Creehan KM; Vandewater SA; Vaillancourt BD; Wright MJ; Janda KD; Taffe MA
Biol Psychiatry; 2013 Apr; 73(8):721-8. PubMed ID: 23098894
[TBL] [Abstract][Full Text] [Related]
10. Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE.
Stevens MW; Rüedi-Bettschen D; Gunnell MG; Tawney R; West CM; Owens SM
Drug Alcohol Depend; 2019 Nov; 204():107484. PubMed ID: 31521953
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
12. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines.
Duryee MJ; Bevins RA; Reichel CM; Murray JE; Dong Y; Thiele GM; Sanderson SD
Vaccine; 2009 May; 27(22):2981-8. PubMed ID: 19428909
[TBL] [Abstract][Full Text] [Related]
13. Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors.
Keller CM; Spence AL; Stevens MW; Owens SM; Guerin GF; Goeders NE
Psychopharmacology (Berl); 2020 Mar; 237(3):655-667. PubMed ID: 31758209
[TBL] [Abstract][Full Text] [Related]
14. Impact of distinct chemical structures for the development of a methamphetamine vaccine.
Moreno AY; Mayorov AV; Janda KD
J Am Chem Soc; 2011 May; 133(17):6587-95. PubMed ID: 21473576
[TBL] [Abstract][Full Text] [Related]
15. Optimization of a methamphetamine conjugate vaccine for antibody production in mice.
Stevens MW; Gunnell MG; Tawney R; Owens SM
Int Immunopharmacol; 2016 Jun; 35():137-141. PubMed ID: 27039212
[TBL] [Abstract][Full Text] [Related]
16. Biological perspectives. Antimethamphetamine antibodies: a new concept for treating methamphetamine users.
Anderson CJ; Gilchrist K; Keltner NL
Perspect Psychiatr Care; 2010 Apr; 46(2):163-7. PubMed ID: 20377804
[No Abstract] [Full Text] [Related]
17. Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats.
Miller ML; Aarde SM; Moreno AY; Creehan KM; Janda KD; Taffe MA
Drug Alcohol Depend; 2015 Aug; 153():29-36. PubMed ID: 26118833
[TBL] [Abstract][Full Text] [Related]
18. The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.
Harris AC; LeSage MG; Shelley D; Perry JL; Pentel PR; Owens SM
PLoS One; 2015; 10(3):e0118787. PubMed ID: 25742165
[TBL] [Abstract][Full Text] [Related]
19. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
20. Vaccines against stimulants: cocaine and MA.
Kosten T; Domingo C; Orson F; Kinsey B
Br J Clin Pharmacol; 2014 Feb; 77(2):368-74. PubMed ID: 23509915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
